Search

Introduction: Migraine, characterized by recurrent headaches and often accompanied by other symptoms like nausea, vomiting, and sensitivity to light and sound, significantly impacts patients' quality of life (QoL) and daily functioning. The global burden of migraines is reflected not only in terms of reduced QoL but also in the form of increased healthcare costs and missed work or school days. While UAE (United Arab Emirates)-specific consensus-based recommendations for the effective use of preventive calcitonin gene-related peptide (CGRP)-based migraine therapies have been published previously, an absence of such regional guidance on the management of acute migraine represents a gap that needs to be urgently addressed. Methods: A task force of eight neurologists from the UAE with expertise in migraine management conducted a comprehensive literature search and developed a set of expert statements on the management of acute migraine that were specific to the UAE context. To ensure diverse perspectives are considered, a Delphi panel comprising 16 neurologists plus the task force members was set up. Consensus was achieved using a modified Delphi survey method. Consensus was predefined as a median rating of 7 or higher without discordance (if > 25% of the Delphi panelists rate an expert statement as 3 or lower on the Likert scale). Expert statements achieving consensus were adopted. Results: The Modified Delphi method was used successfully to achieve consensus on all nine expert statements drafted by the task force. These consensus statements aim to provide a comprehensive guide for UAE healthcare professionals in treating acute migraine. The statements cover all aspects of acute migraine treatment, including what goals to set, the timing of treatment, treatment strategy to use in case of inadequate response to triptans, safety aspects of combining gepants for acute attacks with preventive CGRP-based therapies, special population (pregnant and pediatric patients) considerations, and the management of the most bothersome symptoms (MBS). Conclusions: Adopting these consensus statements on the treatment of acute migraine can help enhance patient care, improve outcomes, and standardize treatment practices in the UAE. The collaborative effort of experts with diverse experiences in developing these consensus statements will strengthen the credibility and applicability of these statements to various healthcare settings in the country. [ABSTRACT FROM AUTHOR]

Introduction: Migraine is a common debilitating neurological disorder affecting a large proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, plays a key role in the pathophysiology of migraine, and the development of therapies targeting the anti-CGRP pathway has revolutionized the field of migraine treatment. Methods: An expert task force of neurologists in the United Arab Emirates (UAE) developed and critically assessed recommendations on the use of CGRP-based therapies in migraine treatment and management in the UAE, based on available published literature. A consensus was reached for each statement by means of an open-voting process, based on a predefined agreement level of at least 60%. Results: The consensus recommendations advocate the need for guidelines for the appropriate use of CGRP-based therapies by defining patient cohorts and appropriate monitoring of therapeutic response as well as standardizing the initiation, assessment, and cessation of treatment. The consensus recommendations were primarily formulated on the basis of international studies, because of the limited availability of regional and local data. As such, they may also act as guidelines for global healthcare providers. Conclusions: These are the first consensus recommendations for the UAE that address the use of CGRP-based therapies in the treatment and management of migraine, integrating both clinical evidence and medical expertise to enhance clinical judgment and decision-making. [ABSTRACT FROM AUTHOR]

Introduction: Inconvenient administration and side effects of some disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) can deter adherence. We evaluated treatment satisfaction with cladribine tablets (CladT) for RMS in the Arabian Gulf. Methods: This was a non-interventional, multicentre, prospective observational study in non-pregnant/lactating adults (aged ≥ 18 years) with RMS eligible for 1st treatment with CladT (EU labelling). The primary outcome was overall treatment satisfaction at 6 months (Treatment Satisfaction Questionnaire for Medication [TSQM]-14, v. 1.4), Global Satisfaction subscale. Secondary endpoints were TSQM-14 scores for convenience, satisfaction with side effects and satisfaction with effectiveness. Patients provided written informed consent. Results: Of 63 patients screened, 58 received CladT and 55 completed the study. Mean age was 33 ± 9 years; mean weight 73 ± 17 kg; 31% male/69% female; mostly from the United Arab Emirates (52%) or Kuwait (30%). All had RMS (mean 0.9 ± 1.1 relapses in the past year), mean Expanded Disability Status Scale (EDSS) 1.4 ± 1.2; 36% were DMT-naïve. Mean [95% CI] score was high for overall treatment satisfaction (77.8 [73.0–82.6]), ease of use (87.4 [83.7–91.0]), tolerability (94.2 [91.0–97.3]) and effectiveness (76.2 [71.6–80.7]). Scores were similar irrespective of DMT history, age, gender, relapse history or EDSS. No relapses or serious treatment-emergent adverse events (TEAE) occurred. Two severe TEAE occurred (fatigue, headache) and 16% reported lymphopenia (two cases of grade 3 lymphopenia). Absolute lymphocyte counts at baseline and 6 months were 2.2 ± 0.8 × 109/L and 1.3 ± 0.3 × 109/L, respectively. Conclusions: Treatment satisfaction, ease of use, tolerability and patient-perceived effectiveness for CladT were high, irrespective of baseline demographics, disease characteristics and prior treatment. [ABSTRACT FROM AUTHOR]

Energy is one of the most fundamental elements to drive economic development. Therefore, it is a significant element of the economic development of UAE. United Arab Emirates (UAE) is keen to exploit the benefits of AI to deliver clean, secure, affordable energy. Thus this paper studied the benefits and user expectations if AI is adopted in the energy sector. This was achieved through a questionnaire amongst the personnel working in the energy sector. From the analysis of 350 completed questionnaire form, this was found that "AI able to increase employees' job performance"; "AI able to improve the customer retention" and "AI bring positive impact to the organization" are three significant benefits of AI implementation in energy sector. Similarly, "Using AI Technology fits well with the way I work", "Interacting with AI Technology is often frustrating" and "Assistance is available if facing difficulty using AI Technology" are three major expectations of the users. Further, the difference of the opinions amongst the respondent groups with different level of working experience and working positions was presented based on comparing means. The findings of this study will encourage the practitioners to implement AI in energy sector. This will also enhance the performance of the energy sector. [ABSTRACT FROM AUTHOR]

Artificial Intelligence (AI) is proved a very effective technique in reducing complexity and making suitable quick decisions for achieving success. Artificial Intelligence is an emerging area and growing fast. It is used successfully in various fields. In UAE also, AI is being used in several sectors. Now the government of UAE has promoted AI in the energy sector to get the maximum of its benefits. Hence, this study evaluated various indicators that affect the promotion of AI in the energy section of the UAE. With the help of a questionnaire survey, 350 questionnaire forms were analyzed to prioritize the parameters affecting AII adoption. From the analysis results it was found that "Organization use AI to provide effective business innovation", "Organizations use AI to align with its business strategy", and "Organization use AI to improve the levels of production" are the key motivating factor to adopt AI. Significant parameters of AI technology include are; AI Technology is user friendly, AI Technology is able to improve the quality of the work and AI Technology fits well with the tasks involved; are reported as significant technological parameters to adopt AI. On the other hand, Referral person is required if facing difficulty with AI technology, and teammate support in using AI technology are essential parameters of the human resource management which affect AI adoption in the energy sector of the UAE. In addition, reliability and normality tests validated the data. Hence, these findings can be used to promote AI and understand the situation for making proper decisions. [ABSTRACT FROM AUTHOR]

The use of immune reconstitution therapies (IRT) in patients with relapsing-remitting multiple sclerosis (RRMS) is associated with a prolonged period of freedom from relapses in the absence of continuously applied therapy. Cladribine tablets is a disease-modifying treatment (DMT) indicated for highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. Treatment with cladribine tablets is effective and well tolerated in patients with active MS disease and have a low burden of monitoring during and following treatment. In this article, an expert group of specialist neurologists involved in the care of patients with MS in the United Arab Emirates provides their consensus recommendations for the practical use of cladribine tablets according to the presenting phenotype of patients with RRMS. The IRT approach may be especially useful for patients with highly active MS insufficiently responsive to treatment with a first-line DMT, those who are likely to adhere poorly to a continuous therapeutic regimen, treatment-naïve patients with high disease activity at first presentation, or patients planning a family who are prepared to wait until at least 6 months after the end of treatment. Information available to date does not suggest an adverse interaction between cladribine tablets and COVID-19 infection. Data are unavailable at this time regarding the efficacy of COVID-19 vaccination in patients treated with cladribine tablets. Robust immunological responses to COVID-19 infection or to other vaccines have been observed in patients receiving this treatment, and treatment with cladribine tablets per se should not represent a barrier to this vaccination. [ABSTRACT FROM AUTHOR]

This paper audits knowledge-sharing research and explores knowledge sharing in the UAE and the banking sector in particular. This research paper is based on a literature review of knowledge sharing and two main theories - social exchange theory and self-determination theory. Each factor is recorded together with analysis of its relevance and relationships in the context of knowledge-sharing constructs and previously used tools for measuring and quantifying and its relationship to different elements. The findings lead to a model that can be applied in a banking organisation and which takes into account the importance of individual factors to knowledge sharing. Other factors related to social exchange (such as personality and knowledge type) are beyond the scope of this research. This study provides a comprehensive framework for helping banking organisations to increase knowledge sharing among their employees. This aggregates existing insights and offers a new framework for knowledge sharing. [ABSTRACT FROM AUTHOR]